Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

OptiGroup acquires Walki Medical Oy in Finland

VeliMark Oy, OptiGroup's Finnish company within the Facility, Safety & Foodservice business area, today announces the acquisition of Walki Medical Oy. Walki Medical is one of Finland's largest distributors of medical supplies with a turnover of EUR 14 million in 2018. The purchase price has not been disclosed. VeliMark, with a turnover of 45 million euros, is a leading supplier of cleaning and facility management supplies in Finland. Through the acquisition, the Facility, Safety & Foodservice business area will broaden its customer offering to include medical supplies to Finnish

Holdings in Company

Faron Pharmaceuticals Oy Company announcement, Turku, 21 November 2019 at 16:00 (EET)  TR-1: Standard form for notification of major holdings   NOTIFICATION OFMAJOR HOLDINGS (tobe sent to therelevantissuer and to theFCA in MicrosoftWord format ifpossible)i 1a. Identity of the Faronissuer or the Pharmaceuticalsunderlying issuer of Ltdexisting sharesto which votingrights areattachedii:1b. Please indicateif the issuer isa non-UK issuer (please

Obducat receives order from German customer at a value of 6 million SEK

OBDUCAT AB (publ) subsidiary Obducat Europe GmbH, a leading supplier of system solutions for lithography processing, has received a repeat order from an existing customer in Germany, for the supply of a MC 204 fully automated resist processing system. The order value amounts to approx.6 million SEK. The fully automated MC 204 resist processing system will be used for production purposes and it will be equipped with a function that enables inline quality control. The ordered tool is the second tool of this type that the customer orders and the purpose is to increase production capacity.

CELLINK launches new bioinks to further strengthen the company’s bioink portfolio

Today, CELLINK launches the next part of a multiphase bioink expansion. This phase includes the release of two new bioink series, the expansion of three existing bioink series, the release of a new thickener series and two products for enhanced cell analysis. With this launch, the company offers a wider range of tools for researchers around the world and further strengthens its bioink portfolio.New bioink series: Chitosan: Chitosan is an abundant biocompatible material which has been used in research related to cartilage, skin and bone tissue engineering. Previously, chitosan’s use

Repurchase of shares in Nobina

During the period 14 November  - 20 November 2019, Nobina AB (publ) (“Nobina”) repurchased a total of 154,410 Nobina shares within the framework of the repurchase programme introduced by the Board of Directors to meet the requirements arising under Nobina’s Share Saving Scheme, meaning securing the delivery of Performance Shares to the participants and securing and covering the costs for any social security contributions that may arise. The repurchase programme, which Nobina announced on 29 October 2019, is being implemented in accordance with the Market Abuse Regulation (EU) No 596/2014 (“

Lifco issues a bond loan of SEK 1,000 million

Lifco  has issued an unsecured bond loan with a tenor of two years within its MTN program (Medium Term Notes). The bond loan amounts to SEK 1,000 million and carries a floating interest rate of three months STIBOR +0.53% annually. The bond issue generated strong investor interest and was oversubscribed. The proceeds from the bond issue will be used for refinancing of existing bank and bond loans. Lifco intends to list the new bonds on the corporate bond list of Nasdaq Stockholm. Danske Bank and SEB acted as lead banks for the issuance. Advokatfirman Vinge has

Optomed Plc applies for its shares to be listed on the official list of Nasdaq Helsinki Ltd

OPTOMED PLC          STOCK EXCHANGE RELEASE                      21 November 2019 at 3 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Optomed Plc (“Optomed” or the “Company”) has today filed a listing application with Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) to list the Company’s

The CEO subscribes for issued shares for SEK 500,000

The energy storage company SaltX Technology - listed on Nasdaq First North Premier Growth Market - carries out a fully guaranteed rights issue of approximately SEK 80 million before issue costs during the period 14 - 28 November. In connection with the ongoing issue, CEO Carl-Johan Linér acquires subscription rights that entitle the holder to subscribe for 90,000 SaltX shares, which means an investment of SEK 500,000.The subscription period runs until November 28, 2019 and subscription rights are traded until November 26 at Nasdaq First North. “SaltX technology for energy storage has a

Cyxone signs a UK contract research organization for six-month toxicology studies with Rabeximod

Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company has signed an agreement with a UK contract research organization (CRO) to conduct the six-month toxicology studies with Rabeximod as required ahead of the Phase IIb study. Preparations for the toxicology studies began immediately with a plan of initiating the studies directly thereafter.Malin Berthold, Head of Project Management at Cyxone, comments “After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent

Medicover adds another EUR 20 million to its outstanding Schuldschein

Medicover  AB (publ) has raised another EUR 20 million by Schuldschein. This new 10 year tranche follows the successfully executed Schuldschein transaction which Medicover closed in October, bringing the total Schuldschein transaction volume to EUR 140 million. The EUR 140 million were issued with tenors of 5, 7 and 10 years, with margins of 1.2%, 1.5% and 1.6% respectively for both fixed and floating rates. Joe Ryan, CFO commented, “Encouraged to see the investor demand, and Medicover’s flexibility to meet that demand has now enabled us to strengthen our

LFV creates smart solutions for the aviation of the future

Automation in aviation and air traffic management can contribute to improved safety, efficiency and sustainability. LFV has, jointly with Linköping University, been conducting research as part of the Automation Program since 2015. On Tuesday, their results were shown to a wider audience in Stockholm.Examples of automation in aviation include the use of artificial intelligence, AI, in air traffic management for improved safety and endurance, monitoring of movements at airports and of aircraft, risk identification in safety-critical environments and automation for training and skills

Lundbergs Interim report January - September 2019

· On September 30, 2019, net asset value after deferred tax amounted to SEK 88.0 billion (SEK 355 per share), compared with SEK 71.4 billion (SEK 288 per share) on December 31, 2018.The corresponding values on November 19, 2019 were SEK 93.7 billion (SEK 378 per share).  · Consolidated net sales amounted to SEK 16,531 m (15,420).   · Profit after financial items amounted to SEK 9,885 m. (8,822). Profit after financial items excluding unrealized changes in value amounted to SEK 6,903 m (5,486).   · Profit after taxes amounted to SEK 8,437 m (8,360) of which non-controlling

Swedish Bublar Group teams up with Amazon Game Tech for the upcoming Hello Kitty augmented reality mobile game and starts pre-registration of the game

Hello Kitty fans and gamers will, as from today, be able to pre-register for the location based mobile game “Hello Kitty AR: Kawaii World” that will go live during 2020. The famous Hello Kitty-character, founded by Japanese Sanrio, is one of the highest grossing media franchises in the world. The game, under production by the XR technology company Bublar, will use Amazon Game Tech´s backend infrastructure. We now celebrate Hello Kitty´s 45th birthday month with an announcement trailer and a landing page. Fans and players that has pre-registered will be pioneers. They will be the first

Transactions in connection with share buy-back programme 14 - 20 November 2019

On 7 November 2019, Vestas initiated a share buy-back programme, ref. Company announcement No. 17/2019 . The programme is implemented in accordance with Regulation No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour” rules). Under the programme, Vestas will buy back shares for an amount up to DKK 1,500m (approx. EUR 200m) in the period

SDLP - Seadrill Partners LLC Announces Third Quarter 2019 Results

Highlights · Operating revenue of $184.8 million · Operating income of $13.0 million · Net loss of $54.2 million · Adjusted EBITDA of $91.9 million · Cash and cash equivalents of $653.6 million · Economic utilization of 95% · Order backlog of $512 million as of November 21, 2019 · 1 cent per common unit distribution for the third quarter of 2019 Financial Results OverviewTotal operating revenues for the third quarter were $184.8 million (2Q19: $178.5 million). The increase was primarily due to a full quarter of operations for the West Aquarius and West

Peptonic closes a private placement transaction with Vidarstiftelsen

Stockholm, November 21st, 2019 - Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that it has closed a private placement transaction with Vidarstiftelsen. The transaction comprised 11 million shares at a subscription price of SEK 2.00 per share. The subscription price was SEK 0.01 above the volume weighted average trading price of the Peptonic share for the period 13th thru 19th of November, 2019. Net proceeds of this placement are SEK 22 million.-      We are honoured and proud that Vidarstiftelsen has decided to invest in Peptonic, says Hans von Celsing, Chairman of the Board

Trustly one of the payment methods at Conotoxia.com

Transactions made at Conotoxia.com can be now funded using the Trustly payment system.Swedish fintech, founded in 2008, offers online payments in 29 European countries, serving over 180 banks across the region and processing over 2 million transactions per month.Trustly does not require registration or software installation. The popularity of this solution is mainly a result of its range and speed of the service as well as optimization for mobile devices.Conotoxia.com users can choose Trustly when paying for currency exchange and money transfer transactions, topping up a currency wallet

Scandion Oncology CEO Newsletter November 2019

Dear Scandion Oncology shareholder,Being able to change drug resistance will have impact on millions of cancer patients world-wide. With the current speed of development and if everything works out, we expect to start the clinical phase II study with SCO-101 treatment by December 2019. In this newsletter, I will give a short summary of what’s to come for SCO-101, with a primary focus on the upcoming phase II clinical trial.Clinical phase II study in patients with drug resistant metastatic colorectal cancerThis is our first clinical study where drug resistant cancer patients will be

LeoVegas interim dividend

At the Annual General Meeting on 29 May 2019 it was decided that the dividend of SEK 1.20 would be paid out in two equal payments. The first payment was distributed on 7 June 2019. The following dates apply to the second payment:· November 29 is the last day to buy the share with the right to the dividend. · Ex-dividend date is 2 December 2019. The stock is traded without giving the buyer the right to the dividend. · Record date is 3 December 2019. The date you need to be registered as a shareholder to be entitled to the dividend. · Distribution by Euroclear Sweden AB on 6 December,

Nightingale Health takes first step to bring preventative health for 8 billion – rolls out consumer blood testing and mobile app

Finland’s Nightingale Health, innovator of an advanced blood-testing technology, today announced their plan to bring preventative health for 8 billion. The company is calling this initiative a new ‘health-creation’ system as the vision behind it is to reshape the present healthcare structure that heavily revolves around sick care. Nightingale wants to move the focus towards prediction and prevention of chronic illness by democratising the benefits of scientific findings and advanced blood-testing.As the first milestone to build a system for ‘health-creation’, the company today launched its

Ahlstrom-Munksjö to divest its glass fiber reinforcement business

AHLSTROM-MUNKSJÖ OYJ, PRESS RELEASE NOVEMBER 21, 2019 at 13:15 EET Ahlstrom-Munksjö has agreed to sell its glass fiber reinforcement business in Mikkeli, Finland, to Vitrulan Composites Oy, a fully owned subsidiary of Vitrulan Group and part of the family-owned industrial holding ADCURAM Group. Ahlstrom-Munksjö’s Mikkeli plant produces glass and carbon based reinforcement fabrics. Main product offering consist of specialty glass fiber reinforcements for wind energy applications as well as for other end-uses including marine and transportation applications as currently manufactured in

Nightingale Health Opens EUR 50-80M Private Placement Round with Carnegie as its Advisor to Bring Nightingale’s Preventative Health Technology to International Markets

Finland’s Nightingale Health, innovator of an advanced blood-testing technology, today opened a private placement round of EUR 50-80M with Carnegie as its advisor to accelerate company’s mission in bringing preventative health for 8 billion. Nightingale is calling this mission a new ‘health-creation’ system as the vision behind it is to reshape the present healthcare structure that heavily revolves around sick care. With its technology, Nightingale is moving the focus towards prediction and prevention of chronic illness by democratising the benefits of scientific findings and advanced blood-

Optomed Plc announces a fixed subscription price for its initial public offering and further information about the listing of its shares; the Finnish language prospectus has been approved

OPTOMED PLC          PRESS RELEASE                    21 November 2019 at 1 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Optomed Plc (“Optomed” or the “Company”) announces the subscription price for the share issue in connection with its initial public offering (the “IPO” or the “

ADDvise receives order worth approximately MSEK 3.3 - Regulatory information

ADDvise Group AB's (publ) subsidiary Sonar Oy has received an order from Helsinki University Hospital worth approximately MSEK 3.3 regarding detectors for Samsung DR systems that will be used for image capturing. Delivery of the equipment is planned to take place at the end of 2019.  For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se Important information: This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on November 21,

There are no items matching the current filter
There are no more items matching the current filter
Back to top